PerkinElmer declares $0.07 dividend
PerkinElmer (PKI) declares $0.07/share quarterly dividend, in line with previous.Forward yield 0.17%Payable Nov. 12; for shareholders of record Oct. 22; ex-div Oct. 21.See PKI Dividend Scorecard, Yield Chart, & Dividend
Seekingalpha · 18h ago
PerkinElmer Board Declares Quarterly Dividend
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock July 23, 2021. This dividend is payable on November 12, 2021 to all shareholders of record at the close of business on October...
Business Wire · 18h ago
--PerkinElmer Keep Quarterly Dividend at $0.07 a Share, Payable Nov. 12 to Shareholders of Record Oct. 22
MT Newswires · 22h ago
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Perkinelmer, Inc.
MT Newswires · 1d ago
The Worldwide Diagnostic/Medical Imaging Industry is Expected to Reach a Value of $43+ Billion by 2026
/PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 1d ago
PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards? · 2d ago
PerkinElmer (PKI) Earnings Expected to Grow: Should You Buy?
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 2d ago
Top Healthcare Stocks for August 2021
These are the healthcare stocks with the best value, fastest growth, and most momentum for August 2021.
Investopedia · 3d ago
PerkinElmer Inc. stock outperforms market on strong trading day · 4d ago
PerkinElmer Stock Sees Improved Technical Ratings; Still Within Buy Zone
PerkinElmer had its Relative Strength (RS) Rating upgraded from 69 to 72 Monday -- a welcome improvement, but still below the 80 or better score you look for. This unique rating measures market leadership by using a 1 (worst) to 99 (best) score that show...
Investor's Business Daily · 4d ago
PerkinElmer Inc. stock underperforms Friday when compared to competitors despite daily gains · 07/16 21:16
Prenatal Testing & Newborn Screening Market Report 2021-2025 & 2030: Non-Invasive, Invasive, Screening Technology, Diagnostic Technology, Hospitals, Diagnostic Centers
/PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 07/16 13:45
Insights on the Long-Read Sequencing Global Market to 2030 - Featuring PerkinElmer, Qiagen and Thermo Fisher Scientific Among Others
The "Global Long-Read Sequencing Market: Focus on Products and Services, Technology, Application, End User, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2030" report has been added to's offerin...
GlobeNewswire · 07/16 08:53
PerkinElmer Inc. stock rises Thursday, outperforms market · 07/15 21:15
miRNA Sequencing And Assay Market Size Worth $597.8 Million By 2028: Grand View Research, Inc.
/PRNewswire/ -- The global size is expected to reach by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 13.0% from 2021 to 2028. Prominent players, such as Illumina, PerkinElmer, Qiagen, and other...
PR Newswire - PRF · 07/14 08:05
3 Stocks With a Solid History of Sales and Earnings Growth
GuruFocus News · 07/13 13:48
Do PerkinElmer's (NYSE:PKI) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Simply Wall St. · 07/13 09:59
PerkinElmer Inc. stock rises Friday, still underperforms market · 07/09 21:15
Live Cell Imaging Global Market Report 2021: COVID-19 Growth And Change announces the release of the report "Live Cell Imaging Global Market Report 2021: COVID-19 Growth And Change" -
GlobeNewswire · 07/09 08:01
If You Invested $1000 in PerkinElmer 10 Years Ago, This Is How Much You'd Have Now · 07/08 12:30
Webull provides a variety of real-time PKI stock news. You can receive the latest news about PerkinElmer through multiple platforms. This information may help you make smarter investment decisions.
About PKI
PerkinElmer Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. Its Discovery & Analytical Solutions segment serves the life sciences and applied markets. Through the Diagnostics Segment, it offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals. It provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its product under various brands, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, FragilEase, Genoglyphix, GSP, PG-Seq, PG-Find, Protein Clear, ProteinEXact and QSight, Glutomatic, Honigs Regression, HyperDSC, Inframatic, LAMBDA, NexION, NEN, OneSource, Opera Phenix, Operetta CLS and OsteoSense.